OncoMatch/Clinical Trials/NCT06011109
Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab
Is NCT06011109 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies APG-157 for glioma.
Treatment: APG-157 — The goal of this interventional study is to evaluate the efficacy of APG-157 in combination with Bevacizumab in subjects with recurrent high-grade glioma. The main questions the study aims to answer are: * Progression-free and overall survival of patients receiving this combination; * Quality of Life (QOL); and * Tumor response on imaging The participants will take APG-157 daily by dissolving two pastilles in their mouth at around breakfast, lunch and dinner time (total of six pastilles per day). The pastilles dissolve in the mouth. The participants will continue to receive Bevacizumab as standard of care.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Disease stage
Required: Stage GRADE III, GRADE IV (WHO)
Grade: IIIIV (WHO)
high grade (aka grade III or IV) glioma
Performance status
ECOG 0–3(Limited self-care)
Prior therapy
Must have received: radiation therapy
Patients must have received prior radiation therapy
Must have received: alkylating agent (temozolomide)
Patients must have received prior...standard temozolomide
Must have received: VEGF inhibitor (bevacizumab)
glioma that has progressed on bevacizumab
Cannot have received: immunotherapy
Immunotherapy...within one full cycle period before first dose of study drug
Cannot have received: chemotherapy
chemotherapy...within one full cycle period before first dose of study drug
Cannot have received: radiotherapy
radiotherapy...within one full cycle period before first dose of study drug
Cannot have received: experimental therapy
experimental therapy within one full cycle period before first dose of study drug
Lab requirements
Blood counts
ANC count ≥1,500/mm3, hemoglobin > 8 g/dL, platelet count ≥100,000/mm3
Kidney function
creatinine < 1.5 x institutional upper limit of normal (ULN)
Liver function
total bilirubin < 1.5 x ULN (unless due to Gilbert's disease); AST or ALT < 2.5 x ULN; serum alkaline phosphatase < 2.5 x ULN
adequate bone marrow reserve (ANC count ≥1,500/mm3, hemoglobin > 8 g/dL, platelet count ≥100,000/mm3); adequate renal and hepatic function with: creatinine < 1.5 x institutional upper limit of normal (ULN); total bilirubin < 1.5 x ULN (unless due to Gilbert's disease); AST or ALT <2.5 x ULN; serum alkaline phosphatase less than 2.5 times the upper limits of normal
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic · Rochester, Minnesota
- University of Nebraska Medical Center · Omaha, Nebraska
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify